News Quantified

INMB – inmune bio inc. - common stock (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology [Yahoo! Finance]

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness [Yahoo! Finance]

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study [Yahoo! Finance]

3.2%

MISS

Sector Outperform

Sector Outperform

Sector Outperform

Sector Outperform

Rodman & Renshaw

Rodman & Renshaw

Form 8-K Inmune Bio, Inc. For: Apr 16

Form 8-K Inmune Bio, Inc. For: Apr 14

Form SCHEDULE 13G/A Inmune Bio, Inc. Filed by: Praetorian PR LLC

Form 8-K Inmune Bio, Inc. For: Apr 03

Form 8-K Inmune Bio, Inc. For: Apr 01

Top News Gainers

3/11 Form 10-K Inmune Bio, Inc. For: Dec 31 26.3%

4/24 Form 424B3 Inmune Bio, Inc. 20.9%

10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%

10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%

12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%

9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%

8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%

4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%

9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%

8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%

Top News Decliners

3/11 INmune Bio Inc. (INMB) CEO R.J. Tesi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -29.8%

10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%

5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%

8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%

8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%

4/21 Form EFFECT Inmune Bio, Inc. -9.7%

4/3 Form EFFECT Inmune Bio, Inc. -8.3%

8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%

3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%

8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day